Focus: Reviva Pharmaceuticals is a public-stage biotech focused on small molecule therapeutics in neurology, headquartered in Cupertino, CA. The company operates a lean clinical pipeline with programs in schizophrenia and rare ophthalmologic conditions.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Reviva Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Reviva Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Reviva Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
What Reviva (RVPH) does that makes it resilient (Technical Weakness) 2026-05-07 - Turnaround Stocks - newser.com
What Reviva (RVPH) does that makes it resilient (Technical Weakness) 2026-05-07 - Turnaround Stocks newser.com
D. Boral Capital downgrades Reviva Pharmaceuticals stock rating to hold - Investing.com
D. Boral Capital downgrades Reviva Pharmaceuticals stock rating to hold Investing.com
$23M on hand, patent push: Reviva lays out 2026 drug roadmap - Stock Titan
$23M on hand, patent push: Reviva lays out 2026 drug roadmap Stock Titan
Reviva Pharmaceuticals Pursues Patent Extension for Brilaroxazine to 2046 and Prepares for Key FDA Milestone in Schizophrenia Program - Minichart
Reviva Pharmaceuticals Pursues Patent Extension for Brilaroxazine to 2046 and Prepares for Key FDA Milestone in Schizophrenia Program Minichart
Reviva (NASDAQ: RVPH) maps brilaroxazine IP push and Phase 3 timeline - Stock Titan
Reviva (NASDAQ: RVPH) maps brilaroxazine IP push and Phase 3 timeline Stock Titan
Reviva Announces Letter to Shareholders - GlobeNewswire
Reviva Announces Letter to Shareholders GlobeNewswire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo